UpdatesPress Release
Solara reported strong Q1’27 with base business revenue up 24% YoY to ₹30.77 Cr and EBITDA up 8% to ₹7.22 Cr.
Solara Active Pharma Sciences LimitedSOLARA · Filed with the exchange
Overall, highest EBITDA (₹6.35 Cr) and PAT (₹1.63 Cr) in 18 quarters.
Debt reduced by ₹13.46 Cr to ₹47.95 Cr.
Strategic options for challenging Ibuprofen business are under evaluation.
No comments yet. Be the first.